AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16167420 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin + clindamycin
Number of subjects: 0
Study 12934183 — intervention group
Group type: EXPERIMENTAL
Intervention: Virosome-formulated, aluminum-free inactivated HAV vaccine
Number of subjects: 239
Study 12934183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study 11054989 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin
Number of subjects: 0
Study 8916753 — intervention group
Group type: COMPARATOR
Intervention: Endocervical and urethral swabs obtained by general practitioners
Number of subjects: 222
Study 8916753 — intervention group
Group type: EXPERIMENTAL
Intervention: First void urine sample, midstream urine sample, and vaginal flush sample collected at home and mailed to the laboratory (polymerase chain reaction)
Number of subjects: 222
Study 8916753 — intervention group
Group type: EXPERIMENTAL
Intervention: First void urine sample, midstream urine sample, and vaginal flush sample collected at home and mailed to the laboratory (ligase chain reaction)
Number of subjects: 222
Study 31177249 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES)
Number of subjects: 20
Study 31177249 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 20
Study 30463813 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg rosuvastatin
Number of subjects: 0
Study 30463813 — intervention group
Group type: COMPARATOR
Intervention: 20 mg atorvastatin
Number of subjects: 0
Study 30463813 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin group
Number of subjects: 0
Study 30463813 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin group
Number of subjects: 0
Study 30463813 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Number of subjects: 0
Study 27936858 — intervention group
Group type: EXPERIMENTAL
Intervention: Observers judging beginner English speakers
Number of subjects: 56
Study 27936858 — intervention group
Group type: EXPERIMENTAL
Intervention: Observers judging nonnative English speakers (advanced and intermediate)
Number of subjects: 56
Study 24758546 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (pPCI)
Number of subjects: 219
Study 24758546 — intervention group
Group type: COMPARATOR
Intervention: pPCI and remote ischemic per-conditioning
Number of subjects: 219
Study 22129843 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin 5 mg/70 kg
Number of subjects: 18
Study 22129843 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin 10 mg/70 kg
Number of subjects: 18
Study 22129843 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin 20 mg/70 kg
Number of subjects: 18
Study 22129843 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin 30 mg/70 kg
Number of subjects: 18
Study 22129843 — intervention group
Group type: COMPARATOR
Intervention: Psilocybin 0 mg/70 kg (placebo)
Number of subjects: 18
Study 19019663 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine (Group B)
Number of subjects: 96
Study 19019663 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% ropivacaine (Group R)
Number of subjects: 96
Study 19019663 — intervention group
Group type: COMPARATOR
Intervention: No FNB (Group C)
Number of subjects: 96
Study 16643550 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan 3 mg (1 mL)
Number of subjects: 24
Study 16643550 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 mL saline)
Number of subjects: 24
Study 12893646 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 800 microg BUD via Turbuhaler
Number of subjects: 15
Study 12893646 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 750 microg FP via Diskus
Number of subjects: 15
Study 12893646 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 200 microg BUD
Number of subjects: 15
Study 12893646 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 200 microg fluticasone dipropionate
Number of subjects: 15
Study 12893646 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of BUD and FP on the same day
Number of subjects: 15
Study 11083533 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 22
Study 11083533 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 22
Study 9177549 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 18
Study 9177549 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg
Number of subjects: 18
Study 9177549 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 18
Study 9177549 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg
Number of subjects: 18
Study 1552406 — intervention group
Group type: EXPERIMENTAL
Intervention: Depakote Sprinkle capsules
Number of subjects: 12
Study 1552406 — intervention group
Group type: COMPARATOR
Intervention: Depakene syrup
Number of subjects: 12
Study 3927481 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate 200 mg 3 times daily
Number of subjects: 40
Study 29326022 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS targeting the left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 60
Study 29326022 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 60
Study 27513854 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4ppm ozone exposure
Number of subjects: 40
Study 27513854 — intervention group
Group type: COMPARATOR
Intervention: Air exposure
Number of subjects: 40
Study 27513854 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine challenge
Number of subjects: 40
Study 24464960 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 21
Study 24464960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 22706026 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-triepitopic antibody fusions
Number of subjects: 0
Study 22706026 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab
Number of subjects: 0
Study 20331585 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphocyte immunotherapy
Number of subjects: 0
Study 20331585 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 18558169 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone and metronidazole (CM) - 2 total doses per day
Number of subjects: 100
Study 18558169 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin, gentamicin, and clindamycin (AGC) - 11 total doses per day
Number of subjects: 100
Study 16645456 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation anesthesia
Number of subjects: 808
Study 16645456 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia
Number of subjects: 808
Study 16645456 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe postoperative pain (numerical rating score > or = 8)
Number of subjects: 808
Study 16645456 — intervention group
Group type: COMPARATOR
Intervention: PONV experience
Number of subjects: 808
Study 12648269 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerec 1 (group 1)
Number of subjects: 496
Study 12648269 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerec 2 (group 2)
Number of subjects: 496
Study 12648269 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerec 2 with wall-spacing software (group 3)
Number of subjects: 496
Study 10757194 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC) applied to the calf under 40 mm Hg pressure for 150 minutes
Number of subjects: 70
Study 10757194 — intervention group
Group type: COMPARATOR
Intervention: Noncompressed calf
Number of subjects: 70
Study 10757194 — intervention group
Group type: EXPERIMENTAL
Intervention: IPC
Number of subjects: 70
Study 8865720 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric intramucosal pH measurement
Number of subjects: 0
Study 8865720 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepato-splanchnic oxygen extraction ratio measurement
Number of subjects: 0
Study 1511147 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback from the Finnish birth register information package sent to 26 hospitals
Number of subjects: 104
Study 1511147 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitals receiving feedback
Number of subjects: 104
Study 1511147 — intervention group
Group type: COMPARATOR
Intervention: Hospitals not receiving feedback (control group)
Number of subjects: 104
Study 6151243 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimipramine (various doses)
Number of subjects: 428
Study 6151243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 428
Study 6151243 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg trimipramine in the evening
Number of subjects: 428
Study 29283791 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 655
Study 27488003 — intervention group
Group type: EXPERIMENTAL
Intervention: Image guided biopsy
Number of subjects: 36
Study 27488003 — intervention group
Group type: COMPARATOR
Intervention: Palpation guided biopsy
Number of subjects: 36
Study 24088617 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Management (WM) intervention including education about regular daily weight monitoring and coping skills, with a WM booklet and scheduled telephone visits
Number of subjects: 66
Study 24088617 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Management (WM) intervention
Number of subjects: 66
Study 24088617 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study 21819548 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal live attenuated influenza vaccine (LAIV)
Number of subjects: 56
Study 19874314 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injections at the temporal hairline
Number of subjects: 40
Study 19874314 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin injections at the temporal hairline plus extra injections at each temporal line
Number of subjects: 40
Study 18037223 — intervention group
Group type: EXPERIMENTAL
Intervention: Epo‐alpha (40,000 IU intravenously each injection, 5 doses within 48 hours)
Number of subjects: 18
Study 18037223 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched controls)
Number of subjects: 18
Study 15925455 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 Gy extended field plus 10 Gy to bulky disease (Arm A)
Number of subjects: 1204
Study 15925455 — intervention group
Group type: COMPARATOR
Intervention: 30 Gy involved field plus 10 Gy to bulky disease (Arm B)
Number of subjects: 1204
Study 15925455 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Arms A and B
Number of subjects: 1204
Study 14743569 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior preperitoneal mesh repair (Group I)
Number of subjects: 60
Study 14743569 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior tension-free repair (Group II)
Number of subjects: 60
Study 11069340 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 0.25 mg with bupivacaine 2.5 mg intrathecally
Number of subjects: 30
Study 11069340 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil 0.25 mg intrathecally
Number of subjects: 30
Study 8627434 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (0.1 mg/kg per dose, administered less than 24 hours after birth and again every 24 hours for six doses)
Number of subjects: 90
Study 8627434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 8627434 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 90
Study 8627434 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin and Placebo
Number of subjects: 90
Study 1317373 — intervention group
Group type: EXPERIMENTAL
Intervention: bradykinin (1.88 x 10(‐3) M)
Number of subjects: 0
Study 1317373 — intervention group
Group type: EXPERIMENTAL
Intervention: capsaicin (3.28 x 10(‐5) M)
Number of subjects: 0
Study 1317373 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 4051254 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusion at a speed of 2 ml/min (Group A)
Number of subjects: 20
Study 4051254 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusion at a speed of 5 ml/min (Group B)
Number of subjects: 20
Study 4051254 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Group A and Group B
Number of subjects: 20
Study 30954990 — intervention group
Group type: EXPERIMENTAL
Intervention: JSS formula
Number of subjects: 104
Study 30954990 — intervention group
Group type: COMPARATOR
Intervention: Modified Shukla's formula
Number of subjects: 104
Study 31225739 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein pasta (10 g protein/serving)
Number of subjects: 12
Study 31225739 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular pasta (7 g protein/serving)
Number of subjects: 12
Study 31225739 — intervention group
Group type: COMPARATOR
Intervention: White rice
Number of subjects: 12
Study 27824398 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin (1 g daily for 12 weeks)
Number of subjects: 84
Study 25939586 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated dietary and lifestyle intervention initiated in infancy
Number of subjects: 457
Study 25939586 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 457
Study 23835718 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab (GA101) 1,600/800 mg
Number of subjects: 40
Study 23835718 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab (GA101) 400/400 mg
Number of subjects: 40
Study 23835718 — intervention group
Group type: COMPARATOR
Intervention: Rituximab-refractory patients
Number of subjects: 40
Study 22085343 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin (1500 to 2000 mg per day)
Number of subjects: 3414
Study 22085343 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo)
Number of subjects: 3414
Study 22085343 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (niacin and placebo)
Number of subjects: 3414
Study 19406146 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive counseling
Number of subjects: 82
Study 19406146 — intervention group
Group type: COMPARATOR
Intervention: Short-term counseling
Number of subjects: 82
Study 19406146 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 82
Study 16126743 — intervention group
Group type: EXPERIMENTAL
Intervention: Group jogging exercise regimen (5 sessions of 50 minutes per week for 8 weeks)
Number of subjects: 49
Study 16126743 — intervention group
Group type: EXPERIMENTAL
Intervention: Group jogging exercise regimen
Number of subjects: 49
Study 16126743 — intervention group
Group type: COMPARATOR
Intervention: Usual daily activities
Number of subjects: 49
Study 15042477 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment with conventional, new atypical or depot neuroleptics
Number of subjects: 307
Study 15042477 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with conventional and depot neuroleptics
Number of subjects: 307
Study 15042477 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine or combination treatment with conventional and atypical neuroleptics
Number of subjects: 307
Study 15042477 — intervention group
Group type: COMPARATOR
Intervention: Conventional, new atypical or depot neuroleptics
Number of subjects: 307
Study 11755553 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal hormone replacement therapy (HRT) with 17 beta-estradiol patches plus oral medroxyprogesterone acetate for 12 cycles of 28 days (group A)
Number of subjects: 70
Study 11755553 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (group B)
Number of subjects: 70
Study 11755553 — intervention group
Group type: COMPARATOR
Intervention: Healthy postmenopausal women without uterine leiomyomas treated with the same regimen as group A (group C)
Number of subjects: 70
Study 9416252 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous extrapleural intercostal nerve block with bupivacaine 0.5% in 1:200,000 epinephrine
Number of subjects: 61
Study 9416252 — intervention group
Group type: COMPARATOR
Intervention: Continuous lumbar epidural block with morphine
Number of subjects: 61
Study 8440099 — intervention group
Group type: EXPERIMENTAL
Intervention: CB0006 (anti-TNF monoclonal antibody) at various doses (0.1 mg/kg, 1.0 mg/kg, 10 mg/kg, or two doses of 1 mg/kg 24 hrs apart)
Number of subjects: 80
Study 8440099 — intervention group
Group type: EXPERIMENTAL
Intervention: CB0006 (high dose anti-TNF monoclonal antibody)
Number of subjects: 80
Study 8440099 — intervention group
Group type: COMPARATOR
Intervention: Standard supportive care and antimicrobial therapy
Number of subjects: 80
Study 8440099 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients in shock at study entry
Number of subjects: 80
Study 3500735 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.0‐2.5 mg kg‐1
Number of subjects: 60
Study 3500735 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone 4‐5 mg kg‐1
Number of subjects: 60
Study 29324496 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided serratus plane block with 0.4 mL/kg of 0.375% ropivacaine
Number of subjects: 90
Study 29324496 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 90
Study 27551937 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous bout (CONT) expending a total of 400 kcal
Number of subjects: 10
Study 27551937 — intervention group
Group type: EXPERIMENTAL
Intervention: Accumulated bout (2×200 kcal) to total 400 kcal
Number of subjects: 10
Study 27551937 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 10
Study 27551937 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous and accumulated bouts
Number of subjects: 10
Study 25281277 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcetrapib 600 mg
Number of subjects: 40
Study 25281277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23587451 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane for 4 months
Number of subjects: 51
Study 23587451 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane for 6 months
Number of subjects: 51
Study 20723260 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine 4 mg
Number of subjects: 0
Study 20723260 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine 8 mg
Number of subjects: 0
Study 20723260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18005140 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon compression (BC)
Number of subjects: 25
Study 15803166 — intervention group
Group type: EXPERIMENTAL
Intervention: Transconjunctival needling
Number of subjects: 21
Study 15803166 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 21
Study 15803166 — intervention group
Group type: COMPARATOR
Intervention: Control group (no EB)
Number of subjects: 21
Study 12663707 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-NL (Wellferon) given daily for 5 days every 3 weeks for up to 12 cycles
Number of subjects: 283
Study 12663707 — intervention group
Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 283
Study 10872763 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative patient‐controlled analgesia and continuous epidural block (group 2)
Number of subjects: 109
Study 10872763 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐shot epidural analgesia, postoperative patient‐controlled analgesia, and continuous epidural block (group 3)
Number of subjects: 109
Study 10872763 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 1)
Number of subjects: 109
Study 8653161 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine without epinephrine
Number of subjects: 41
Study 8653161 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 41
Study 8653161 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ketorolac (administered 3.5 hours before procedure)
Number of subjects: 41
Study 1521715 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 9
Study 1521715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 1521715 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulglycotide
Number of subjects: 9
Study 7041623 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (N‐CPAP)
Number of subjects: 18
Study 7041623 — intervention group
Group type: COMPARATOR
Intervention: Oxygen by hood (Control)
Number of subjects: 18
Study 30730860 — intervention group
Group type: COMPARATOR
Intervention: Rectal indomethacin alone
Number of subjects: 960
Study 30730860 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of rectal indomethacin and topical spray of epinephrine
Number of subjects: 960
Study 29034576 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-g curcumin
Number of subjects: 18
Study 29034576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 26627366 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam plus levetiracetam (2.5 g)
Number of subjects: 203
Study 26627366 — intervention group
Group type: COMPARATOR
Intervention: Clonazepam plus placebo
Number of subjects: 203
Study 24930819 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation intervention (daily practice during Asian history course)
Number of subjects: 101
Study 24930819 — intervention group
Group type: COMPARATOR
Intervention: Active control (African history course with matched experiential activity)
Number of subjects: 101
Study 18165936 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylcellulose pills (2-week supply), told it was a cognitive enhancer
Number of subjects: 40
Study 18165936 — intervention group
Group type: COMPARATOR
Intervention: No pills (control group)
Number of subjects: 40
Study 15369494 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic relaxation for 15 minutes during recovery from the first ambulation after surgery
Number of subjects: 102
Study 15369494 — intervention group
Group type: COMPARATOR
Intervention: Control group (no systematic relaxation)
Number of subjects: 102
Study 11695508 — intervention group
Group type: EXPERIMENTAL
Intervention: Low salt diet
Number of subjects: 15